RxSight (RXST) Receivables (2020 - 2026)

RxSight (RXST) has reported Receivables for 7 consecutive years, with $78.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables rose 179.85% year-over-year to $78.5 million; the trailing twelve-month figure through Jun 2026 stood at $78.5 million (up 179.85% YoY), and the FY2025 full-year result was $23.4 million, down 22.19% from the prior year.
• Receivables advanced to $78.5 million in Q2 2026 per RXST's latest filing, from $22.4 million in the prior quarter.
• Across five years, Receivables topped out at $78.5 million in Q2 2026 and bottomed at $5.6 million in Q1 2022.
• Historically, Receivables has averaged $22.5 million across 5 years, with a median of $22.0 million in 2024.
• The widest YoY moves for Receivables: up 179.85% in 2026, down 27.51% in 2026.
• Over 5 years, Receivables stood at $11.0 million in 2022, then jumped by 85.11% to $20.3 million in 2023, then jumped by 48.17% to $30.0 million in 2024, then slipped by 22.19% to $23.4 million in 2025, then jumped by 235.8% to $78.5 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $78.5 million, $22.4 million, and $23.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.